Disclaimer

Bozo.Finance. A Groundbreaking NFTxTOKEN Solution Revolutionizing Decentralized Finance.

Source Node:
Time Stamp: February 1, 2024 10:46 AM - Modified On: February 1, 2024 - Published By:
Source Cluster:
Republished By Plato

  Bozo.Finance / Bozo Hybrid In an innovative leap forward for the DeFi space, Bozo Hybrid announces the launch of its revolutionary platform - a first-of-its-kind NFTxTOKEN hybrid that is reshaping the landscape of liquidity and asset interchangeability. The Game-Changing Innovation of Bozo HYBRID Bozo HYBRID is not just another project in the blockchain space. It represents a paradigm shift, a true DeFi 2.0 model, by integrating non-fungible tokens (NFTs) with fungible tokens ($bozo tokens) to create a two-way liquidity portal. This hybrid approach is a breakthrough in the market,

Curio and Deep Isolation Sign MOU to Advance Nuclear Waste Disposal Technologies.

Source Node:
Time Stamp: December 7, 2023 3:23 PM - Modified On: December 7, 2023 - Published By:
Source Cluster:
Republished By Plato

Washington, D.C, December 7, 2023 — Curio, a trailblazer in nuclear technology solutions, and Deep Isolation, an innovator in nuclear waste disposal, have entered into a Memorandum of Understanding (MOU) to collectively drive forward the development of advanced technologies for efficient and secure disposal of high-level nuclear waste (HLW). Under this MOU, both Curio and Deep Isolation will mutually collaborate and exchange critical information for the use of Deep Isolation’s Universal Canister System (UCS) and patented directional drilling solution for deep borehole disposal for the isolation and management of HLW

NKGEN Biotech Received FDA Approval for Clinical Trials of SKN01 NK Cell Therapy in Alzheimer’s Disease Treatment.

Source Node:
Time Stamp: October 24, 2023 11:55 AM - Modified On: October 24, 2023 - Published By:
Source Cluster:
Republished By Plato

Summary: Progress in Neurodegenerative Research:  NKGen’s Phase 1/2a Clinical Trial for SNK01 on Track for End-of-Year Initiation SANTA ANA, Calif., Oct. 24, 2023 (Plato / Amplifi) -- Today, NKGen Biotech Inc. (Nasdaq: NKGN), a trailblazer in the field of autologous, allogeneic, and CAR-NK natural killer cell therapeutics, proudly announced the progression of its SNK01 program targeting Alzheimer’s Disease (AD), backed by the green light from the U.S. Food and Drug Administration (FDA) for its Investigational New Drug (IND) application. NKGen is gearing up to initiate its Phase 1/2a clinical trial

GPOPPLUS (GPOX:US:OTC) Announces Impressive Revenue Results

Source Node:
Time Stamp: August 1, 2023 5:58 AM - Modified On: August 1, 2023 - Published By:
Source Cluster:
Republished By Plato

GPOPlus+, (GPOX:US:OTC) a leading provider and distributor of products for convenience stores and specialty retailers, gas stations, smoke shops, has recently announced an impressive surge in revenues during the fourth quarter of the year. The company reported a staggering 320% increase in its financial performance, marking a significant milestone for the organization. GPOPlus+ offers a unique technology driven direct store delivery model (“DSD”) that is creating both significant increases in revenue as well as improved unit economics with greater efficiencies yielding higher margins.  The Company has implemented this program successfully